Kyntra Bio projects interim clinical data for FG-3246 in late 2026 while securing funding through 2028.
Kyntra Bio (KYNB) announced plans to release interim clinical data for its antibody-drug conjugate FG-3246 in Q4 2026. The company extended its cash runway into 2028, reducing near-term financing risks.
Management highlighted progress in its portfolio during the Q1 2026 earnings call, emphasizing FG-3246, a first-in-class therapy targeting CD46, and its companion PET imaging agent. No prior interim data readouts were disclosed for comparison.
The update follows consistent operational execution, though market reaction details were not provided in the source.